The city of Madison, Wisconsin, currently has 42 active clinical trials seeking participants for Breast Cancer research studies.
TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery
Recruiting
This phase II trial studies how well TPIV100 and sargramostim work in treating patients with HER2 positive, stage II-III breast cancer that has residual disease after chemotherapy prior to surgery. It also studies why some HER2 positive breast cancer patients respond better to chemotherapy in combination with trastuzumab and pertuzumab. TPIV100 is a type of vaccine made from HER2 peptide that may help the body build an effective immune response to kill tumor cells that express HER2. Sargramostim... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
12/15/2023
Locations: Dean Hematology and Oncology Clinic, Madison, Wisconsin
Conditions: Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer
Recruiting
This is a 3-arm study stratified by plasma ctDNA. Patients with residual TNBC disease after pre-operative therapy will be assigned to 1 of 3 Arms based on plasma ctDNA positivity and genomic marker(s).
Gender:
All
Ages:
18 years and above
Trial Updated:
09/22/2023
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Breast Cancer, Triple Negative Breast Cancer
Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype
Recruiting
HARMONIA is an international, multicenter, randomized, open-label and phase III study. The primary objective of this study is to demonstrate that the combination of ribociclib with endocrine therapy (letrozole or fulvestrant) is superior to palbociclib with endocrine therapy (letrozole or fulvestrant) in prolonging progression-free survival in patients with advanced HR+/HER2- and HER2-E breast cancer. The study will enroll approximately 456 patients with HER2-E disease from approximately 95 site... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2023
Locations: Unv. Wisconsin, Madison, Wisconsin
Conditions: Metastatic Breast Cancer
FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer
Recruiting
Despite broad advancements in endocrine therapy for ERα+ breast cancer, resistance ultimately develops. A common driver of resistance are known ESR1 mutations that lead to constitutively active receptor signaling and transcriptional regulation that is always "turned on" despite the absence of estrogen. Patients with ESR1 mutations are expected to have decreased binding affinity for tamoxifen and thus may be underdosed on standard therapy. [18F]-fluoroestradiol Positron Emission Tomography/Comput... Read More
Gender:
All
Ages:
19 years and above
Trial Updated:
06/14/2023
Locations: University of Wisconsin Carbone Cancer Center, Madison, Wisconsin +1 locations
Conditions: ERα+ Breast Cancer, ESR1 Gene Mutation
Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy
Recruiting
Eligible subjects will be assigned to study treatment arms by their treating oncologist, rather than by the study. The drug, dose, and schedule of administration will be determined by the treating physician per NCCN guidelines for standard of care chemotherapy regimens for recurrent or metastatic breast cancer. Study treatment arms include: Taxane (nab-paclitaxel or paclitaxel), Eribulin, Vinorelbine, Ixabepilone, or the control arm (non-microtubule targeted chemotherapies such as doxorubicin, c... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/11/2023
Locations: University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
Conditions: Breast Cancer, Breast Neoplasms
DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer
Recruiting
A randomized, Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, stage II-III, Estrogen Receptor positive, HER-2 negative breast cancer (DARE)
Gender:
All
Ages:
All
Trial Updated:
03/20/2023
Locations: University of Wisconsin Clinical Science Center, Madison, Wisconsin
Conditions: Breast Cancer